Hello, Well, it’s certainly been a week. Between drug price hearings and disgruntled Bristol-Myers Squibb investors, I’m sure a lot of folks in the industry are looking forward to the week winding down. But before it does, I wanted to share some of the stories that preoccupied the healthcare team here at Business Insider this week. Are you new to our weekly newsletter? You can sign up here .